Dynavax inks universal vaccine pact with Novartis

Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will provide a trivalent flu vaccine to Dynavax for use in the universal vaccine in exchange for an exclusive option to negotiate a licensing deal. No financial details were divulged in their announcement.

Vaccine makers have been scrambling to come up with a universal flu vaccine that can defend against a variety of flu strains. Every year health officials target three strains--a guessing game that often misses the mark. A universal vaccine would help remove some of that guesswork and do a much better job at protecting populations

- read the report from the San Francisco Business Times

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.